5th Annual Advances in Immuno-Oncology

Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions developing immuno-oncology therapies and tools.

Over 60 presentations, case studies and panel discussions focussed on the key opportunities and challenges in immuno-oncology, from therapeutic strategies and biomarker development through to clinical research.

PLUS, interactive opportunities including:

·         Workshop on Accelerating the Treatment & Response Rate of Cancer Immunotherapies

·         6 roundtable discussions on key industry growth areas within immuno-oncology

View Agenda: http://bit.ly/2NX4yWS

Day One – 21 May 2020

·         Discovery of Immuno-Oncology Therapies: Inhibitory Pathway & Cell-Based Approaches

·         Translational Immuno-Oncology

·         Personalised Therapies for Immuno-Oncology

Day Two – 22 May 2020

·         Discovery of Immuno-Oncology Therapies: Antibody and Virus-Based Approaches

·         Preclinical Development: Screening, Assays and Modelling in Immuno-Oncology

·         Clinical Research & Trials in Immuno- Oncology

Celine Adessi, Senior Director, Group Head, Oncology, Clinical Safety, F. Hoffmann-La Roche Ltd.

Roman Kischel, Director, Amgen

Andrew Pierce, Associate Director, AstraZeneca

Mahendra Deonarain, Chief Executive and Science Officer, Director of R&D, Antikor

Omid Vafa, Chief Business Officer, Teneo Bio

Jochen Strizker, Senior Vice President Immunotherapy, Themis Bioscience